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Neurological and psychiatric symptoms are consequences of substance abuse in schizophrenia 
and non-schizophrenia patients. The present case–control study examined changes in substance 
abuse/dependence, and neurological and psychiatric symptoms in substance abusers with [dual 
diagnosis (DD) group, n = 26] and without schizophrenia [substance use disorder (SUD) group, 
n = 24] and in non-abusing schizophrenia patients (SCZ group, n = 23) undergoing 12-week 
treatment with the atypical antipsychotic, quetiapine. Neurological and psychiatric symptoms 
were evaluated with the Positive and Negative Syndrome Scale, the Calgary Depression Scale 
for Schizophrenia, the Extrapyramidal Symptoms Rating Scale, and the Barnes Akathisia Rating 
Scale. At endpoint, DD and SCZ patients were receiving significantly higher doses of quetiapine 
(mean = 554 and 478 mg/day, respectively), relative to SUD patients (mean = 150 mg/day). 
We found that SUD patients showed greater improvement in weekly dollars spent on alcohol 
and drugs and SUD severity, compared to DD patients. At endpoint, there was no significant 
difference in dollars spent, but DD patients still had a higher mean SUD severity. Interestingly, 
DD patients had significantly higher parkinsonism and depression than SCZ patients at baseline 
and endpoint. On the other hand, we found that SUD patients had significantly more akathisia at 
baseline, improved more than SCZ patients, and this was related to cannabis abuse/dependence. 
Finally, SUD patients improved more in Positive and Negative Syndrome Scale positive scores 
than DD and SCZ patients. Taken together, our results provide evidence for increased vulnerability 
to the adverse effects of alcohol and drugs in schizophrenia patients. They also suggest that 
substance abuse/withdrawal may mimic some symptoms of schizophrenia. Future studies will 
need to determine the role quetiapine played in these improvements.
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more neurological and psychiatric symptoms than non-abusing 
schizophrenia patients (Bersani et al., 2005; Potvin et al., 2007, 
2009; Harrison et al., 2008).
Current evidence suggests that atypical antipsychotic treat-
ment is associated with improvements in psychiatric symp-
toms in schizophrenia (Lieberman et al., 2005; Lee et al., 2009; 
Nakamura et al., 2009). Due to these benefits, as well as their low 
propensity to induce neurological symptoms, atypical antipsy-
chotics are increasingly being tried as treatments for substance 
abuse in psychotic and non-psychotic patients (for review, see 
Zhornitsky et al., 2010b). Indeed, previous studies in single- 
and DD patients suggest that atypical antipsychotics may lead 
to improvements in alcohol use disorder (Littrell et al., 2001; 
Martinotti et al., 2007, 2009). Some studies have also found 
atypical antipsychotics to improve cannabis use disorder in 
DD patients (Green et al., 2003; van Nimwegen et al., 2008). 
However, irrespective of their efficacy for actually relieving sub-
stance abuse, we know very little about the effects of atypical 
IntroductIon
Schizophrenia is the most disabling psychiatric disorder, according 
to the Global Burden of Disease study (Eaton et al., 2008). Important 
contributors to disability in schizophrenia are psychiatric (e.g., pos-
itive, negative, and depressive symptoms) and neurological symp-
toms (e.g., parkinsonism, dyskinesia, and akathisia; Patterson et al., 
1998; Villalta-Gil et al., 2006; Aubin et al., 2009). Compounding 
these problems is the nearly 50% lifetime prevalence of substance 
use disorder (SUD) associated with schizophrenia (Regier et al., 
1990). In non-psychotic individuals, substance use is associated 
with neurological and psychiatric symptoms (Mauri et al., 2007; 
Zhornitsky et al., 2010a). In schizophrenia patients, substance use 
has a negative impact on the course of the pathology. Compared to 
non-abusing patients, dual diagnosis (DD) schizophrenia patients 
are more frequently hospitalized, non-compliant with treatment, 
suicidal, impulsive and violent, homeless and unemployed, and 
they have more legal and health problems (Mueser et al., 1998; 
Negrete, 2003). Similarly, there is evidence that DD patients have 
Edited by:
Lorenzo Leggio, Brown University, USA
Reviewed by:
Giovanni Martinotti, Catholic University 
of Rome, Italy
David Gorelick, National Institute on 
Drug Abuse, USA
*Correspondence:
Stéphane Potvin, Centre de recherche 
Fernand-Seguin, 7331 Hochelaga, 
Montréal, QC, Canada H1N 3V2. 
e-mail: stephane.potvin@umontreal.ca
Frontiers in Psychiatry | Addictive Disorders  May 2011 | Volume 2 | Article 22 | 2
Zhornitsky et al. Schizophrenia, SUD and quetiapine
Calgary Depression Scale for Schizophrenia (CDSS; Addington 
et al., 1993). For more information on clinical assessments, refer 
to Potvin et al. (2006a).
Sud aSSeSSmentS
Quantities of substances used in the last week were also registered, 
using the TimeLine Follow-Back (TLFB) procedure (Sobell and 
Sobell, 1992). Quantities used were noted for all substances. Amount 
spent on substances was calculated based on the value market in 
Quebec province (Canada). To complement our evaluation of SUDs, 
urine screenings were performed on weeks 0 and 12, for cannabi-
noids, opiates, and psychostimulants. SUD severity was also evalu-
ated using an adapted eight-item scale, based on DSM-IV criteria 
of substance dependence. Two trained students and a trained nurse 
scored [from 0 (no problem) to 5 (severe problem)] the patient’s SUD 
severity on the following items: (1) loss of control; (2) time spent on 
PAS; (3) impact of SUDs on social life; (4) impact of SUDs on daily 
occupations; (5) physical impact of SUDs; (6) psychiatric impact of 
SUDs; (7) impact of SUDs on compliance; and (8) ability to enjoy 
pleasures other than substance use. For more information on SUD 
assessments, refer to Potvin et al. (2006a) and Rizkallah et al. (2010).
StatIStIcal analySeS
Baseline and endpoint differences between the DD, SCZ, and SUD 
groups were analyzed using one-way analyses of variance (ANOVA) 
with group as the independent variable. Changes in substance 
abuse, neurological and psychiatric symptoms were analyzed using 
mixed ANOVA with group as the independent variable and time as 
the repeated measure. Multiple comparisons were performed using 
the Bonferroni correction. The influence of potential confounds 
on improvements in neurological and psychiatric symptoms were 
analyzed using analyses of covariance (ANCOVA). Dichotomous 
variables were evaluated using Pearson’s Chi-square test. The level 
of significance was set at p < 0.05. Last-observation carried forward 
(LOCF) was used. Statistical analyses were performed using the 
Predictive Analytics SoftWare (PASW; version 18).
reSultS
PartIcIPantS
Thirty-one DD patients were prescribed quetiapine; of these, two 
were lost-to-follow-up and three dropped out due to side-effects 
(Figure 1). Twenty-five SCZ patients were prescribed quetiapine; 
of these, two were lost-to-follow-up. Thirty-three SUD patients 
were prescribed quetiapine; of these, two were lost-to-follow-up, 
two dropped out due to side-effects, three dropped out due to 
relapse, and clinical data was missing for two patients. Therefore, 
LOCF analysis was available for 26, 23, and 24 patients in the DD, 
SCZ, and SUD group, respectively.
SocIodemograPhIc varIableS
Significant differences were found for age (F = 5.5, p = 0.006), gen-
der (χ2 = 7.1, p = 0.03), and quetiapine dose (F = 22.1, p = 0.0001) 
between the three groups (Table 1). By contrast, no significant dif-
ferences were found between the groups in ethnicity, psychiatric 
diagnosis, type of substance(s) used, number of hospitalizations, 
and baseline antipsychotic.
antipsychotics on neurological and psychiatric symptoms when 
prescribed to substance abusers with or without comorbid psy-
chosis. This is an important area of study because any residual 
symptoms and deficits may act as negative reinforcers to main-
tain the cycle of addiction (Koob and Le Moal, 2001), and may 
impair their social functioning and quality of life (Addington 
and Addington, 1997; Lahmek et al., 2009).
The present study examined substance use outcomes and neu-
rological and psychiatric symptoms in substance abusers with and 
without schizophrenia and in non-abusing schizophrenia patients 
undergoing a 12-week treatment with the atypical antipsychotic 
quetiapine. This antipsychotic was chosen because it has previously 
been shown to improve substance use outcomes in psychotic and 
non-psychotic patients (Potvin et al., 2006a; Kampman et al., 2007; 
Martinotti et al., 2008; Rizkallah et al., 2010) and is an effective 
monotherapy for anxiety and depressive disorders (for review, see 
Zhornitsky et al., 2011), while also producing little or no neurologi-
cal symptoms (Weiden, 2007). Importantly, this is the first study 
of its kind to trace the evolution of neurological and psychiatric 
symptoms in all three groups of patients undergoing a homogenous 
antipsychotic treatment. This study is complementary to earlier 
studies by Potvin et al. (2006a) and Rizkallah et al. (2010), which 
reported substance abuse and clinical outcomes for DD patients 
and non-schizophrenia substance abusers.
materIalS and methodS
PartIcIPantS
Three groups of participants were recruited, namely: (i) substance-
abusing patients with schizophrenia-spectrum disorders (schizo-
phrenia, schizoaffective disorder, schizophreniform disorder; DD 
group); (ii) non-psychotic substance abusers in detoxification 
(SUD group); and (iii) schizophrenia patients with comorbid sub-
stance abuse (SCZ group). Psychiatric and SUD diagnoses were 
by well-trained psychiatrists (Lahcen Aït Bentaleb, Olivier Lipp, 
and Emmanuel Stip) and physicians (Jean-Pierre Chiasson), and 
were all based on DSM-IV criteria. SUD diagnoses were comple-
mented with urine drug screenings. In the SUD group, there were 
two diagnoses of borderline personality disorder and two diagnoses 
of substance-induced psychotic disorder (DSM-IV). All partici-
pants signed a detailed consent form. The study was approved by 
the local ethics committee.
For all three groups, exclusion criteria were: (i) patients already 
on clozapine or quetiapine; (ii) patients hospitalized in a psychiatric 
unit; (iii) pregnancy; (iv) female subjects of childbearing potential 
or inadequate contraception; and (v) clinically meaningful unsta-
ble, renal, hepatic, cardiovascular, respiratory, cerebrovascular, or 
other serious, progressive physical disease. For the DD and SCZ 
groups, patients were excluded if their total score on the Positive 
and Negative Syndrome Scale (PANSS; Kay et al., 1987) was lower 
than 65. Adjuvant medications were allowed in all three groups.
clInIcal aSSeSSmentS
Neurological symptoms were evaluated with the Extrapyramidal 
Symptoms Rating Scale (ESRS; Chouinard et al., 1980). Akathisia 
was evaluated with the Barnes Akathisia Scale (BAS; Barnes, 1989). 
Psychiatric symptoms were measured using the PANSS and the 
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SubStance uSe outcomeS
Additionally, SUD patients had significantly higher SUD severity 
than DD patients at baseline (F = 11.3, p = 0.002), but DD patients 
had significantly higher SUD severity at endpoint (F = 14.7, p < 0.001; 
Table 2). Moreover, SUD patients spent significantly more dollars per 
week on alcohol and drugs at baseline (F = 11.1, p = 0.002), but there 
was no significant difference between the groups at endpoint. There 
was also a significant main effect of time for SUD severity (F = 106.4, 
p < 0.001) and dollars per week (F = 21.5, p < 0.001). Finally, SUD 
patients improved significantly more than DD patients in SUD sever-
ity (F = 41.7, p < 0.001) and dollars per week (F = 16, p < 0.001).
neurologIcal SymPtomS
Dual diagnosis patients had significantly more parkinsonism than SCZ 
patients at baseline (F = 3.6, p = 0.03) and significantly more than SUD 
patients at endpoint (F = 4.2, p = 0.02; Table 3). In addition, SUD 
patients had significantly higher akathisia scores than SCZ patients at 
baseline (F = 3.1, p = 0.05), but not at endpoint. No significant differ-
ences were observed for dyskinesia at baseline or endpoint. Dystonia 
was not present in significant numbers in our sample (data not shown). 
Repeated measures analysis revealed that there was a main effect of 
time for parkinsonism (F = 9.5, p = 0.003) and akathisia (F = 6.9, 
p = 0.01), but not dyskinesia. Changes in parkinsonism and dyskinesia 
did not differ significantly between the groups. Akathisia improved 
significantly more from baseline to endpoint in SUD relative to DD 
and SCZ patients (F = 5.3, p = 0.02). The between-group differences in 
improvements in akathisia were no longer significant when changes in 
SUD outcomes were considered as covariates (p = n.s). Sub-analyses of 
drug-specific effects revealed that improvements in akathisia in SUD 
patients were particular to cannabis abusers (F = 7.2, p = 0.01). They 
also revealed that improvements in parkinsonism in DD patients were 
particular to stimulant abusers (F = 5.3, p = 0.03).
PSychIatrIc SymPtomS
At baseline (F = 13.7, p < 0.001) and endpoint, DD and SCZ 
patients had significantly higher PANSS negative scores com-
pared to SUD patients (F = 23.6, p < 0.001; Table 4). In addition, 
Figure 1 | Participant disposition. ITT, intention-to-treat; LOCF, last-
observation carried forward; DD, dual diagnosis group; SCZ, non-abusing 
schizophrenia group; SUD, non-schizophrenia substance abuser group.
Table 1 | Sociodemographic variables.
Variable  Statistics  
  (multiple comparisons)*
Age (yeArS)
DD 30.5 (9.5) F = 5.5, p = 0.006 (SCZ > DD)
SCZ 40.6 (12.4) 
SUD 37.5 (11) 
gender
DD 24 Male, 2 female χ2 = 7.1, p = 0.03
SCZ 15 Male, 8 female 
SUD 15 Male, 9 female  
eThniciTy
DD 24 Caucasian, 2 other χ2 = 1, p = 0.6
SCZ 20 Caucasian, 3 other 
SUD 20 Caucasian, 4 other 
QueTiAPine doSe (mg/dAy)
DD 553.9 (254.9) F = 22.1, p = 0.0001 
  (DD and SCZ > SUD)
SCZ 478.3 (272) 
SUD 150 (117.7) 
hoSPiTAlizATionS
DD 2.8 (3) F = 0.8, p = 0.4
SCZ 3.6 (3.7) 
SUD – 
diAgnoSiS
DD 15 SZ, 9 SA, 2 SF χ2 = 0.5, p = 0.8
SCZ 13 SZ, 5 SA, 1 SF 
SUD – 
BASeline AnTiPSychoTic (ATyPicAl:TyPicAl:BoTh:drug-Free)+
DD 18:4:3:1 χ2 = 4, p = 0.3
SCZ 14:4:0:3 
SUD – 
Alcohol ABuSe/dePendence
DD 12 Yes, 14 no χ2 = 0.3, p = 0.6
SCZ – 
SUD 13 Yes, 11 no 
cAnnABiS ABuSe/dePendence
DD 15 Yes, 11 no χ2 = 0.1, p = 0.7
SCZ – 
SUD 15 Yes, 9 no 
STimulAnT ABuSe/dePendence
DD 9 Yes, 17 no χ2 = 0.3, p = 0.6
SCZ – 
SUD 10 Yes, 14 no 
mulTi-SuBSTAnce ABuSe/dePendence
DD 10 Yes, 16 no χ2 = 2, p = 0.2
SCZ – 
SUD 14 Yes 10 no
SZ, schizophrenia; SA, schizoaffective disorder; SF, schizophreniform disorder; 
DD, dual diagnosis group; SCZ, non-abusing schizophrenia group; SUD, 
non-schizophrenia substance abuser group.
*Bonferroni correction.
+Missing data for one subject in SCZ group.
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Table 2 | Substance use disorder outcomes.
Variable Baseline endpoint Statistics (multiple comparisons*)
Sud SeVeriTy
DD 22.1 (4.4) 17.2 (7.7) Baseline: F = 11.3, p = 0.002; time: F = 106.4, p < 0.001; group × time: F = 41.7, 
SUD 28.3 (7.9) 7.1 (10.4) p < 0.001; endpoint: F = 14.7, p < 0.001
dollArS Per weeK
DD 93.4 (65.4) 61.8 (60) Baseline: F = 11.1, p = 0.002; time: F = 21.5, p < 0.001; group × time: F = 16,  
SUD 467.1 (546.3) 34 (72.7) p < 0.001; endpoint: F = 2.1, p = 0.2
DD, dual diagnosis group; SCZ, non-abusing schizophrenia group; SUD, non-schizophrenia substance abuser group.
*Bonferroni correction.
Table 3 | neurological symptoms at baseline and endpoint.
Variable Baseline endpoint Statistics (multiple comparisons*)
PArKinSoniSm
DD 9.7 (14.1) 4.7 (5.9) Baseline: F = 3.6, p = 0.03 (DD > SCZ); time: F = 9.5, p = 0.003;  
SCZ 2.5 (2.6) 2.1 (2.4) group × time: F = 1.8, p = 0.2; endpoint: F = 4.2, p = 0.02 (DD > SUD)
SUD 5.7 (6.9) 1.5 (3.4) 
AKAThiSiA
DD 0.7 (0.9) 0.4 (0.6) Baseline: F = 3.1, p = 0.05 (SUD > SCZ#); time: F = 6.9, 
SCZ 0.6 (1.1) 0.7 (1.2) p = 0.01; group × time: F = 5.3, p = 0.02 (SUD > SCZ); endpoint: F = 1, p = 0.4
\SUD 1.3 (1.2) 0.3 (0.7) 
dySKineSiA
DD 0.7 (1.8) 0.2 (0.7) Baseline: F = 2.7, p = 0.07; time: F = 1.1, p = 0.3; group × time:  
SCZ 1.9 (3.4) 1.4 (3.3) F = 0.4, p = 0.7; endpoint: F = 2.5, p = 0.09
SUD 0.4 (1.1) 0.5 (1.3)
DD, dual diagnosis group; SCZ, non-abusing schizophrenia group; SUD, non-schizophrenia substance abuser group.
*Bonferroni correction.
#LSD correction.
depression scores were significantly higher in DD compared to 
SCZ patients at baseline (F = 3.2, p = 0.05). Moreover, they were 
significantly higher in DD compared to SCZ and SUD patients 
at endpoint (F = 5.7, p = 0.005). No differences were observed in 
PANSS positive scores at baseline; however, PANSS positive symp-
toms were significantly higher in DD and SCZ patients at endpoint 
(F = 16.9, p < 0.001). Repeated measures analysis revealed that 
was a significant main effect of time for PANSS positive (F = 38, 
Table 4 | Psychiatric symptoms at baseline and endpoint.
Variable Baseline endpoint Statistics (multiple comparisons*)
PAnSS PoSiTiVe
DD 18.3 (4.3) 15.6 (4) Baseline: F = 1.4, p = 0.3; time: F = 38, p < 0.001; group × time: F = 5.3, p = 0.007 
SCZ 17.1 (4.3) 15.3 (4.3) (SUD > DD and SCZ); endpoint: F = 16.9, p < 0.001 (DD and SCZ > SUD)
SUD 16.2 (5.4) 10 (2.7)
PAnSS negATiVe
DD 19.5 (4.8) 16.4 (5) Baseline: F = 13.7, p < 0.001 (DD and SCZ > SUD); time: F = 28.7, p < 0.001;  
SCZ 17.1 (4.8) 16.4 (4.7) group × time: F = 2.3, p = 0.1; endpoint: F = 23.6, p < 0.001 (DD and SCZ > SUD)
SUD 12.5 (4.8) 8.9 (3.2)
dePreSSion
DD 6.8 (5) 3.9 (3.6) Baseline: F = 3.2, p = 0.05 (DD > SCZ); time: F = 36.6, p < 0.001; group × time:  
SCZ 3.6 (4.6) 1.2 (1.6) F = 1.1, p = 0.4; endpoint: F = 5.7, p = 0.005 (DD > SCZ and SUD)
SUD 6 (4.1)  1.8 (3.1)
DD, dual diagnosis group; SCZ, non-abusing schizophrenia group; SUD, non-schizophrenia substance abuser group; PANSS, Positive and Negative Syndrome Scale.
*Bonferroni correction.
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revealed that improvements in parkinsonism were only significant 
in abusers of psychostimulants in the DD group. Obviously, the 
increase in parkinsonism in DD patients, relative to SUD patients, 
may be attributed to the fact that schizophrenia patients concomi-
tantly take antipsychotics, which may interact with psychostimu-
lants to increase parkinsonism (Potvin et al., 2006b; Maat et al., 
2008). Indeed – when given acutely – cocaine and amphetamine 
stimulate striatal dopaminergic neurotransmission by blocking 
and reversing the dopamine transporter, respectively. However, 
their long-term abuse is associated with significant reduction in 
dopamine D
2
 receptor availability in the striatum that may last for 
months after detoxification, similar to the striatal dopaminergic 
deficit observed in Parkinson’s disease (Volkow et al., 2004). Taken 
together, these results suggest that schizophrenia patients are more 
vulnerable to develop parkinsonism than SUD patients, even when 
taking small amounts of psychostimulants.
An unexpected result of the present study is the elevated akathisia 
at baseline in SUD patients. Intriguingly, a subanalysis revealed that 
the improvements in akathisia were found in cannabis abusers, 
which is consistent with reports of restlessness and physical ten-
sion/agitation among patients undergoing cannabis withdrawal 
(Kouri and Pope, 2000; Budney et al., 2003). Moreover, we found 
that akathisia improved significantly more in SUD patients, rela-
tive to SCZ patients, which is consistent with previous accounts 
of cannabinoid withdrawal. Overall, these results suggest that the 
endogenous cannabinoid system plays a role in the manifestation 
of akathisia, which may be related to its role in motor behavior (El 
Manira and Kyriakatos, 2010).
Analysis of psychiatric symptoms revealed that DD and SCZ 
patients had significantly more negative symptoms, relative to SUD 
patients at baseline and endpoint. This is consistent with evidence 
suggesting that negative symptoms are relatively unique to schizo-
phrenia (Zhornitsky et al., 2010a). By contrast, we found that depres-
sive symptoms were nearly twice as high in DD and over one and a 
half times higher in SUD compared to SCZ patients. This finding 
is in line with research showing that substance abuse is a risk fac-
tor for the development of depression (Lynskey et al., 2004; Falck 
et al., 2006; Pozzi et al., 2008) as well as with our meta-analysis of 
3283 patients showing that addicted schizophrenia patients experi-
ence more severe depressive symptoms compared to non-abusing 
patients (Potvin et al., 2007). At study endpoint, depression scores 
were persistently elevated in DD patients. Taken together, these 
results are consistent with increased vulnerability in schizophrenia 
patients in response to drugs of abuse. Finally, at baseline – but not 
at endpoint – we found that all three groups had equally significant 
levels of positive symptoms, which is consistent with observations of 
elevated positive symptoms in non-schizophrenia substance abusers 
(Mauri et al., 2007; Lapworth et al., 2009). Interestingly, however, 
despite their high levels of positive symptoms, only two SUD patients 
responded to substance-induced psychosis criteria (SIPD; DSM-IV). 
Since the DSM-IV notes that a patient must have persistent delusions 
or hallucinations coupled with a lack of insight to be diagnosed with 
SIPD, we examined in more detail which PANSS positive items were 
most elevated at baseline in our SUD group. We found that the most 
elevated items (mean score ≈ 3) were hostility, excitement and para-
noia/suspiciousness; symptoms which may manifest during post-
intoxication or withdrawal but do not signify the presence of SIPD, 
p < 0.001) and negative symptoms (F = 28.7, p < 0.001) as well 
as depression (F = 36.6, p < 0.001; Table 4). Changes in negative 
and depressive symptoms did not differ significantly between the 
groups (Table 4). However, PANSS positive symptoms improved 
significantly more in SUD patients from baseline to endpoint, 
compared to DD and SCZ patients (F = 5.3, p = 0.007). There 
was no effect of age, gender, and dose when these variables were 
entered into the ANCOVA model. However, the finding of a greater 
improvement in positive symptoms in SUD patients disappeared 
after changes in SUD severity in time were considered as a covari-
ate (p = n.s).
dIScuSSIon
The present study aimed to examine changes in substance use, 
as well as neurological symptoms and psychiatric symptoms in 
substance abusers with and without schizophrenia and in non-
abusing schizophrenia patients undergoing 12-week treatment 
with quetiapine We found that SUD patients had a higher mean 
SUD severity, spent significantly more dollars weekly on alco-
hol and drugs at baseline and showed greater improvement in 
these variables, compared to DD patients. Nevertheless, at end-
point, there was no significant difference in dollars spent, but DD 
patients still had a higher mean SUD severity. Interestingly, DD 
patients had significantly higher parkinsonism and depression 
than SCZ patients at baseline and endpoint. On the other hand, 
we found that SUD patients had significantly more akathisia at 
baseline, improved more than SCZ patients and this was related 
to cannabis abuse/dependence. Finally, there were no significant 
differences in PANSS positive scores between the groups; however, 
SUD patients improved more and the differences were significant 
at endpoint.
In the present study, we found that SUD patients improved 
more in terms of SUD outcomes than DD patients. One explana-
tion for this result could be that SUD patients had a significantly 
higher SUD severity at baseline, leading to the greater improve-
ment. In addition, our SUD group began the study in detoxifica-
tion, whereas our DD group were active users, suggesting that it 
was easier for the former patients to quit alcohol and/or drugs. 
Alternatively, these results suggest that it may be more difficult 
for schizophrenia patients to reduce or quit their substance use 
(Ziedonis et al., 2005). Importantly, DD patients still had a higher 
mean SUD severity than SUD patients at endpoint, despite spend-
ing similar amounts on alcohol and drugs. This finding is consistent 
with reports that substance abuse can have negative consequences 
on schizophrenia patients even when they use small amounts, infre-
quently (Ziedonis et al., 2005). It is also consistent with evidence of 
increased dopaminergic sensitivity in schizophrenia. Indeed, posi-
tron emission tomography (PET) studies have reported increased 
D
2
/D
3
 occupancy in schizophrenia patients in response to ampheta-
mine challenge, relative to healthy controls (Laruelle et al., 1996; 
Abi-Dargham et al., 1998).
In terms of EPS, we found that DD patients had elevated par-
kinsonism at baseline, relative to SCZ and SUD patients, despite 
using significantly smaller quantities of alcohol and/or drugs. At 
endpoint, DD patients still had elevated parkinsonism relative to 
the other two groups, although they were taking similar amounts of 
these substances relative to SUD patients. Interestingly, a  subanalysis 
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